US-based Conmed is focusing on higher growth margin business lines, exiting its gastroenterology business to streamline operations. Shares fell nearly 10% on the NYSE post-announcement. Conmed’s flagship product was the VIABIL biliary stent, distributed exclusively in the US and Canada until now. Olympus Corporation will take over distribution starting in 2026. Conmed expects minimal impact on revenues for fiscal year 2025. The company’s CEO is optimistic about the strategic move, positioning Conmed for long-term success in surgical innovation. The exit is expected to result in an earnings per share dilution of $0.45-$0.55 in 2026.

Read more at Yahoo Finance: Conmed to exit gastroenterology business